During this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, speaks with Bethany Kalich, PharmD, CLS, a Cardiovascular Medical Director and Asset Lead for the US Medical Team. Tune in for a conversation on the critical role of pharmacists and healthcare agencies in addressing gender inequalities in cardiovascular health. Sheila Arquette, President & CEO of NASP, speaks with Bethany Kalich, PharmD, CLS ..read more

Episode 3 of the NASP Post Show! In this episode we talk with Nicholas Ruiz - keycentrix Richard Brook - Better Health Worldwide / NPRT Russel Robbins - PurpleLab Saumya Rawat - Pharmesol David Bronstein - Specialty Pharmacy Continuum Tim McLeroy - Noble International ..read more

Jennifer Donovan, Pharm D, is the vice president of clinical services at Shields Health Solutions. In this role, Jen leads the Clinical Services, Training and Outcomes teams. She’s responsible for ensuring Shields provides best-in-class patient care that’s evidence-based and adheres to external requirements, working cross functionally with various departments. Prior to Shields, Jen was the Associate Dean for the School of Pharmacy – Worcester/Manchester and Professor of Pharmacy Practice at Massachusetts College of Pharmacy and Health Sciences in Worcester, MA. Jen earned a Doctor of Pharmacy ..read more

Episode 2 of the NASP Post Show! In this episode we talk with   Jonathan Levitt  Jonathan Ogurchak - STACK Zeal Specialty Julie Allen - Policy Advocacy NASP Luis Rodriguez  Mark Conklin - Free Mark Health Mike Baldzicki - NASP     ..read more

This episode features conversations with   Aleeta Postell & Sabeen Hasnie - Walmart Specialty Pharmacy Amanda Awe PharmD - VPL Cecelia Byers - Surescripts Chris Antypas, PharmD Dan Brooks - Brooks Group Jeffrey Baird ..read more

During this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, sits down with Dr. Paige Kilian, Chief Medical Officer (CMO) for Inovalon, to discuss the outsized role administrative burden is playing in driving primary care physicians and pharmacists out of the patient communities that need them, what we need to do to fix it, and what is possible once we do ..read more

Success in launching new therapies for rare diseases (RDs) implies the ability for the manufacturer to achieve a level of reimbursed price and a level of market access that are commercially viable on the market. Access to RD therapies is challenging because the legal and policy frameworks may be absent, funding may be insufficient and/or payers do not see the justification with the prices for these therapies. The industry has, however, a real opportunity to partner with healthcare stakeholders.  There needs to be continued support to provide the education towards payers, drive evidence-ba ..read more

Continuing advances in cell and gene therapy (CGT) are transforming the pharmacy and point of care ecosystem. Recent launches of new CGTs have yielded mixed results on getting the right therapy to the right patients.  The CGTs pipeline and approvals are likely to rise dramatically in the near future. In 2024 alone, up to 21 cell therapy launches and as many as 31 gene therapy launches are on the horizon. Therefore, the launch readiness for these products should be effective so that the therapies can benefit as many patients as possible while ensuring a sufficient return on manufacturers ..read more

During this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, sits down with Tim McLeroy, Executive Director of Marketing & Patient Services at Noble. They discuss challenges patients face when beginning therapeutic treatment, solutions to provide the training and support that patients need, the impacts of biosimilars and telehealth on patient experience, and cost-effective approaches for patient training and onboarding. Sheila Arquette, RPh, President & CEO of NASP; Tim McLeroy, Executive Director of Marketing & Patient Services at Noble ..read more

Rare diseases affect nearly 10% of the US population and transformative changes to research and development, as well as modernized regulatory pathways, have accelerated the entry of orphan drugs to the market. This uptick has necessitated discussions on how best to manage these conditions to ensure the right therapy is provided to the right patient at the right time. This episode is a first step in creating an open and transparent dialogue on the challenges faced by insurers in a resource constrained healthcare environment. As the focus will offer listeners a view of the latest trends in rare ..read more